期刊文献+

去势抵抗性前列腺癌人工神经网络预后预测模型的建立及其准确性分析 被引量:1

Partial logistic artificial neural network model for prognosis prediction of castration resistant prostate cancer and its evaluation
原文传递
导出
摘要 目的试图建立去势抵抗性前列腺癌(CRPC)患者预后预测模型,并评估其准确性。方法回顾分析2007年1月至2012年1月在中山大学附属第三医院就诊的去势抵抗性前列腺癌病例,收集入组时年龄、基线PSA值、PSA倍增时间、血红蛋白、碱性磷酸酶、白蛋白、是否采用多西他赛三周化疗方案治疗等因素,运用Cox单因素分析筛选潜在预后预测变量后,分别以Cox多因素回归分析与部分指数回归人工神经网络建立预后预测模型,以ROC曲线下面积评估模型准确性。结果 Cox多因素回归模型的ROC曲线下面积为0.69,部分指数回归人工神经网络模型ROC曲线下面积为0.84。结论通过部分指数人工神经网络建立的预后预测模型可以纳入不符合比例风险假定的临床数据,改善预测准确度,较好的预测去势抵抗性前列腺癌患者的预后情况。 Objectives To ereat and evaluate the efficacy of prognosis prediction model for castration resistant prostate cancer (CRPC) patients. Methods Records of patients diagnosed with CRPC from January 2007 to January 2012 in the Third Affiliated Hospital of Sun Yat-sen University were reviewed. Data of age, PSA baseline, PSA doubling time, hemoglobin, alkaline phosphatase, albumin, treatment regime, liver metastasis and other candidate prognosis factors were collected. After excluding unrelated factors with Cox univariate regression, prognosis models were created with Cox multivariate regression and partial logistic artificial neural network (PLANN), respectively. Both models were evaluated with area under ROC curve method. Results Area under ROC curve for Cox multivariate regression model was 0.69, and 0.84 for PLANN model. Conclusions Variables that don't satisfy proportional hazard assumption can be included with PLANN method, improving the efficacy of the model, and providing more accurate prediction on prognosis of CRPC patients.
作者 郑骏明 高新
出处 《中华腔镜泌尿外科杂志(电子版)》 2013年第6期7-10,共4页 Chinese Journal of Endourology(Electronic Edition)
基金 国家自然科学基金(81172430) 中山大学临床研究5010计划项目(2007028)
关键词 前列腺癌 预后 人工神经网络 Prostate cancer Prognosis Artificial neural networks
  • 相关文献

参考文献19

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 2余红梅..Cox比例风险回归模型诊断及预测有关问题的研究[D].第四军医大学,2001:
  • 3Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol6gicas Espafiolas (English Edition), 2011, 35(10): 565-579. 被引量:1
  • 4Biganzoli E, Boracchi P, Marubini E. A general framework for neural network models on censored survival data. Neural Networks, 2002, 15(2): 209-218. 被引量:1
  • 5Lee JL, Kim JE, Ahn JH, et al. Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in korea. Cancer Research and Treatment, 2010, 42(1): 12. 被引量:1
  • 6Nakano K, Ohta S, Komatsu K, et al. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. BMC urology, 2012, 12(1): 3. 被引量:1
  • 7瞿元元,戴波,孔蕴毅,叶定伟,姚旭东,张世林,张海梁,马春光.影响多西他赛化疗的转移性去势抵抗性前列腺癌患者总生存期的预后因素分析[J].中国癌症杂志,2012,22(10):779-783. 被引量:9
  • 8Miyake H, Sakai I, Terakawa T, et al. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol, 2013, 31 (6): 733-738. 被引量:1
  • 9Vollmer RT, Kantoff PW, Dawson NA, et al. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin Cancer Res, 1999, 5(4): 831-837. 被引量:1
  • 10Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology, 68(3): 565-569. 被引量:1

二级参考文献15

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 3TANNOCK I F, de WIT R, BERRY W R, et al. Docetaxel plus prednisone or mitoxantrone plus prcdnisone for advanced prostate cancer [ J ] . N Engl J Med, 2004, 351(15): 1502- 1512. 被引量:1
  • 4PETRYLAK D P, TANGEN C M, HUSSAIN M H, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ] . N Engl J Med, 2004, 351(15): 1513-1520. 被引量:1
  • 5PETRYLAK D P. The treatment of hormone-refractory prostate cancer: docetaxel and beyond [ J ] . Reviews Urol, 2006, 8(2): 48-55. 被引量:1
  • 6GROOPMAN J E, 1TRI L M. Chemotherapy-induced anemia in adults: incidence and treatment [ J ] . J Nalt Cancer Inst, 1999, 91(19): 1616-1634. 被引量:1
  • 7CARO J J, SALAS M, WARD A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review [ J ] . Cancer, 2001, 91(12): 2214-2221. 被引量:1
  • 8TONG W G, QUINTAS-CARDAMA A, KADIA T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system [J].Cancer, 2012, 118(18): 4462- 4470. 被引量:1
  • 9BELBARAKA R, TREDAN O, RAY-COQUARD I, et al. Factors of interrupting chemotherapy in patients with advanced non-small cell lung cancer [ J ] . BMC Res Notes, 2010, 3: 164. 被引量:1
  • 10ARMSTRONG A J, GARRET'F-MAYER E, de WIT R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer [ J ] . Clin Cancer Res, 2010, 16(1): 203-211. 被引量:1

共引文献175

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部